Details for Patent: 6,888,027
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 6,888,027 protect, and when does it expire?
Patent 6,888,027 protects BELEODAQ and is included in one NDA.
This patent has eighteen patent family members in eleven countries.
Summary for Patent: 6,888,027
| Title: | Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors |
| Abstract: | This invention pertains to certain active carbamic acid compounds which inhibit HDAC activity and which have the following formula: (I) A is an aryl group; Q.sup.1 is a covalent bond or an aryl leader group; J is a sulfonamide linkage selected from: --S(.dbd.O).sub.2 NR.sup.1 -- and --NR.sup.1 S(.dbd.O).sub.2 --; R1 is a sulfonamido substituent; and, Q.sup.2 is an acid leader group; with the proviso that if J is --S(.dbd.O).sub.2 NR.sup.1 --, then Q.sup.1 is an aryl leader group; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and, e.g., to inhibit proliferative conditions, such as cancer and psoriasis. ##STR1## |
| Inventor(s): | Watkins; Clare J (Abingdon, GB), Romero-Martin; Maria Rosario (Didcot, GB), Moore; Kathryn G (Abingdon, GB), Ritchie; James (Abingdon, GB), Finn; Paul W (Abingdon, GB), Kalvinsh; Ivars (Riga, LV), Loza; Einars (Riga, LV), Dikovska; Klara (Riga, LV), Gailite; Vija (Riga, LV), Vorona; Maxim (Riga, LV), Piskunova; Irina (Riga, LV), Starchenkov; Igor (Riga, LV), Andrianov; Victor (Riga, LV), Harris; C. John (Sittingbourne, GB), Duffy; James E. S. (Sittingbourne, GB) |
| Assignee: | Topotarget UK Limited (Abingdon, GB) |
| Application Number: | 10/381,790 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 6,888,027 |
|
Patent Claim Types: see list of patent claims | Compound; Composition; Use; |
Drugs Protected by US Patent 6,888,027
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acrotech | BELEODAQ | belinostat | POWDER;INTRAVENOUS | 206256-001 | Jul 3, 2014 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY PERIPHERAL T-CELL LYMPHOMA (PTCL). | See Plans and Pricing | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 6,888,027
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 0023986 | Sep 29, 2000 |
| PCT Information | |||
| PCT Filed | September 27, 2001 | PCT Application Number: | PCT/GB01/04326 |
| PCT Publication Date: | April 18, 2002 | PCT Publication Number: | WO02/30879 |
International Family Members for US Patent 6,888,027
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2001290131 | See Plans and Pricing | |||
| Australia | 9013101 | See Plans and Pricing | |||
| Canada | 2423744 | See Plans and Pricing | |||
| Canada | 2765409 | See Plans and Pricing | |||
| Cyprus | 1114818 | See Plans and Pricing | |||
| Denmark | 1328510 | See Plans and Pricing | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
